Bone metabolism and the cardiometabolic syndrome: pathophysiologic insights.
Accumulating evidence indicates that the several components of the cardiometabolic syndrome such as hypertension, increased triglycerides, and reduced high-density lipoprotein cholesterol are also risk factors for low bone mineral density. Furthermore, some of the underlying risk factors for atherosclerosis in the cardiometabolic syndrome, such as inflammation, also play a major role in the pathogenesis of osteoporosis, the most common metabolic bone disease. In this article for the premiere issue of the Journal of the CardioMetabolic Syndrome, the author presents the current evidence of the interaction of bone metabolism and the cardiometabolic syndrome, highlighting the major research in this area and discussing the potential of therapeutic agents that will be useful in the treatment of osteoporosis as well as atherosclerosis.
McFarlane
Samy I
SI
Division of Endocrinology, Diabetes and Hypertension, SUNY-Downstate and Kings County Hospital Center, Brooklyn, NY 11203, USA. smcfarlane@downstate.edu
D015519:Bone Density / Q000502:physiology*; D001851:Bone Diseases, Metabolic / Q000453:epidemiology / Q000209:etiology* / Q000378:metabolism; D006801:Humans; D024821:Metabolic Syndrome / Q000150:complications* / Q000378:metabolism; D015995:Prevalence; D012307:Risk Factors; D014481:United States / Q000453:epidemiology